StockData

Ironwood Pharmaceuticals vs Phathom Pharmaceuticals

IRWD and PHAT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IRWD and PHAT compare

Ironwood Pharmaceuticals is the larger company, worth 1.8 times as much as Phathom Pharmaceuticals ($801M against $447M).

Phathom Pharmaceuticals grew revenue faster over the last twelve months (86.8% versus 26.2% for Ironwood Pharmaceuticals).

Ironwood Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 33.4% compared with −30.2% at Phathom Pharmaceuticals.

Ironwood Pharmaceuticals scores higher on the StockData Score (12 against 4 for Phathom Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIRWDPHAT
Size and price
Market cap$801M$447M
Share price$4.85$5.50
Change, 1 year43.9%−62.2%
Change, 5 years−56.5%−72.2%
Beta (5Y)1.051.73
Employees100371
StockData Score
Total score12 (better)4
Valuation score6 (better)1
Growth score2 (better)1
Performance score2 (better)1
Health score2 (better)1
Dividend score00
Valuation
P/E6.3×–
P/S2.1×1.6× (better)
EV/EBITDA3.1×–
FCF yield–−4.7%
Fair value$12.87–
Margin of safety62.3%–
Growth
Revenue growth (TTM)26.2%86.8% (better)
Revenue growth, 5Y average−5.3%–
EPS growth, 5Y average−25.6%–
Profitability
Gross margin–80.7%
Operating margin60.1% (better)−9.3%
Net margin33.4% (better)−30.2%
FCF margin–−7.7%
Financial health
Interest coverage7.2× (better)−0.4×
Current ratio6.06 (better)1.76
Altman Z-score−1.91 (better)−4.87
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions97.2%88.7%
Held by insiders16.0%12.2%
Insider net buying, 12 months−$22.6M$0 (better)
Short interest, % of float10.7%12.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.